MyMD Pharmaceuticals Announces New Data from Comparative Study on Lead Compound MYMD-1

MyMD Pharmaceuticals Announces New Data from Comparative Study on Lead Compound MYMD-1

  • New data shows MYMD-1 has key differentiators and capabilities compared to existing TNF inhibitor drugs
  • Company plans to initiate Phase II trial with a leading academic institution

BALTIMORE–(BUSINESS WIRE)–MyMD Pharmaceuticals, Inc. (“MyMD”), a clinical stage pharmaceutical company committed to extending healthy lifespan by focusing on developing two therapeutic platforms, today announced new data from a study conducted by Eurofins Discovery (ERF.FP) Phenotypic Center of Excellence (“Eurofins”) comparing the biological activities of MyMD’s lead compound MYMD-1, with leading FDA approved TNF inhibitors (TNFi).

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210707005497/en/

MYMD-1 is being developed to treat autoimmune and age-related diseases, and to slow aging thereby increasing life-span. The drug has shown effectiveness in regulating the immune system, in preclinical studies, by targeting the root causes of inflammation and performing as a selective inhibitor of tumor necrosis factor-alpha (TNF-a), a driver of chronic inflammation.

The recent Eurofins study found that when compared to commercially available TNFi biological drugs, MYMD-1 had significant activity demonstrating anti-proliferative effects – the effect of inhibiting cell growth. Data also demonstrated that none of the biological drugs selected for the comparison study proved to be anti-proliferative to any of the primary cell types assessed.

“This data continues to validate our concerted efforts to move forward in bringing MYMD-1 to the market and its promising potential to treat a myriad of inflammatory and autoimmune-related diseases,” said Chris Chapman, M.D., President, Director and Chief Medical Officer of MyMD. “We remain encouraged as we continue our evaluations of MYMD-1 for efficacy and safety – especially as studies continue to suggest we may be able to address many of the concerns that are associated with the current drugs on the market today in these disease areas.”

The current FDA approved TNFi biological drugs selected for the comparative study treat a number of inflammatory and autoimmune diseases, including Crohn’s disease, ulcerative colitis, rheumatoid arthritis, psoriasis, psoriatic arthritis, and more. Acumen Research and Consulting confirmed TNF-α inhibitors are the most prescribed drugs by revenue globally, at $40 billion per year.

“Current TNF-a inhibitors available today, while effective, come with an array of adverse effects and concerns for patients,” said Adam Kaplin, M.D., Ph.D, Chief Scientific Officer for MyMD. “Many have the risk of causing neurotoxicity, as they are unable to cross the blood–brain barrier; this is one of the key differentiators and capabilities of MYMD-1, which crosses the blood-brain barrier. We also found that MYMD-1’s selectivity allows it to only block overactive TNF-a in lymphocytes that participate in autoimmune diseases, leaving TNF-a synthesized in macrophages to be produced to help coordinate the initial response to acute infections. This should remove the increased risk of infection, associated with all TNFi biological drugs used today.”

“The power of the BioMAP Platform lies in the ability to compare a compound’s biological profile, or fingerprint, against a large reference database of profiles from approved drugs and tool compounds,” said Alison O’Mahony, Ph.D., Vice President of Translational Biology at Eurofins Discovery. “These advanced analytics provide a human-centric, data-driven approach to phenotypic discovery for clients.”

The study was completed using the BioMAP® Diversity PLUS® Panel for broad phenotypic profiling and screening from Eurofins Discovery. The BioMAP Diversity PLUS Panel provides biologically relevant in vitromodels of human disease and is used to analyze drug candidate compounds, from discovery to preclinical safety. BioMAP Diversity PLUS systems are made of human primary cell-based assays modeling complex tissue and disease biology of organs. BioMAP Diversity PLUS informs a drug candidate’s potency, selectivity, safety, mechanism of action and disease indication. Additionally, these findings can provide actionable insights to help progress the right molecules to further clinical testing.

MyMD will continue conducting studies with Eurofins to determine the efficacy of MYMD-1 and its key differentiators when compared to current drugs on the market. These efforts continue to support MyMD’s efforts to move forward in Phase 2 clinical studies.

About MyMD Pharmaceuticals, Inc.

MyMD is a clinical stage pharmaceutical company committed to extending healthy lifespan by focusing on developing two therapeutic platforms. MYMD-1 is a drug platform based on a clinical stage small molecule that regulates the immunometabolic system to control TNF-α and other pro-inflammatory cytokines. MYMD-1 is being developed to treat autoimmune diseases, including those currently treated with non-selective TNF-α blocking drugs, and aging and longevity. Supera-CBD is a drug platform based on a novel (patent pending) synthetic derivative of cannabidiol (CBD) that targets numerous key receptors including CB2 and opioid receptors and inhibits monoamine oxidase. Supera-CBD is being developed to address the rapidly growing CBD market, that includes FDA approved drugs and CBD products not currently regulated as a drug. For more information, visit www.mymd.com.

About Eurofins – the global leader in bio-analysis

Eurofins is testing for life. Eurofins is a global leader in food, environment, and pharmaceutical product testing. It is also one of the market leaders in testing and laboratory services for genomics, discovery pharmacology, forensics, advanced material sciences and has a rapidly developing presence in highly specialised and molecular clinical diagnostic testing.

With over 50,000 staff across a network of more than 800 laboratories in over 50 countries, Eurofins’ companies offer a portfolio of over 200,000 analytical methods.

Eurofins Shares are listed on Euronext Paris Stock Exchange.

Cautionary Statement Regarding Forward-Looking Statements

This press release may contain forward-looking statements. These forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause actual results, performance or achievements to be materially different from any expected future results, performance, or achievements. Forward-looking statements speak only as of the date they are made and none of MyMD nor its affiliates assume any duty to update forward-looking statements. Words such as “anticipate,” “believe,” “could,” “estimate,” “expect,” “may,” “plan,” “will,” “would” and other similar expressions are intended to identify these forward-looking statements. Important factors that could cause actual results to differ materially from those indicated by such forward-looking statements include, without limitation: the timing of, and MyMD’s ability to, obtain and maintain regulatory approvals for clinical trials of MyMD’s pharmaceutical candidates; the timing and results of MyMD’s planned clinical trials for its pharmaceutical candidates; the amount of funds MyMD requires for its pharmaceutical candidates; increased levels of competition; changes in political, economic or regulatory conditions generally and in the markets in which MyMD operates; MyMD’s ability to retain and attract senior management and other key employees; MyMD’s ability to quickly and effectively respond to new technological developments; MyMD’s ability to protect its trade secrets or other proprietary rights, operate without infringing upon the proprietary rights of others and prevent others from infringing on MyMD’s proprietary rights; and the impact of the ongoing COVID-19 pandemic on MyMD’s results of operations, business plan and the global economy. A discussion of these and other factors with respect to MyMD is set forth in the Quarterly Report on Form 10-Q for the quarterly period ended March 31, 2021, filed by MyMD on May 18, 2021. Forward-looking statements speak only as of the date they are made and MyMD disclaims any intention or obligation to revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Investor Contact:

Robert Schatz

(646) 421-9523

[email protected]

www.mymd.com

Media Contact:

Will Johnson

201-465-8019

[email protected]

www.antennagroup.com

KEYWORDS: United States North America Maryland

INDUSTRY KEYWORDS: Biotechnology Other Health Health Pharmaceutical Clinical Trials

MEDIA:

Logo
Logo
Photo
Photo

The Trade Desk Launches TD7, Venture Capital Arm to Invest in Open Internet Start-Ups

The Trade Desk Launches TD7, Venture Capital Arm to Invest in Open Internet Start-Ups

First Investment in Algorithmic Ad Optimization Innovator, Chalice

LOS ANGELES–(BUSINESS WIRE)–
Global advertising technology leader, The Trade Desk (NASDAQ:TTD) today announced the launch of an internal venture capital arm, TD7, to invest in technology innovators focused on the open internet. As part of this announcement, The Trade Desk highlighted an initial investment in Chalice, a company pioneering new approaches to algorithmic ad buying.

“Advancing the open internet is core to our mission at The Trade Desk. An open, transparent and competitive internet is in everyone’s interests – advertisers, publishers and consumers – and we look forward to investing in companies that share this vision,” said Jeff Green, Co-Founder and CEO, The Trade Desk. “This is an important moment for The Trade Desk. The TD7 name derives from the $7 million in venture capital it took for The Trade Desk to become profitable. And we’ve been profitable ever since. We want to see more smart ad tech people succeed in small and disciplined companies because that will help the whole industry innovate and grow.”

The announcement comes as The Trade Desk launches its new trading platform, Solimar, bringing major advances in ad-buying for the open internet. Solimar’s many features are also available via Application Programming Interfaces (APIs), allowing developers to build on the company’s innovations to create their own ad tech offerings.

“The Trade Desk’s platform APIs have been key in establishing Chalice as an Open Internet ad tech innovator. The Trade Desk’s approach leaves room for industry innovation, in a way that is not possible with Walled Gardens,” said Adam Heimlich, CEO of Chalice. “We look forward to building on this progress with The Trade Desk as TD7’s first venture investment.”

About The Trade Desk

The Trade Desk™ is a technology company that empowers buyers of advertising. Through its self-service, cloud-based platform, ad buyers can create, manage, and optimize digital advertising campaigns across ad formats and devices. Integrations with major data, inventory, and publisher partners ensure maximum reach and decisioning capabilities, and enterprise APIs enable custom development on top of the platform. Headquartered in Ventura, CA, The Trade Desk has offices across North America, Europe, and Asia Pacific. To learn more, visit thetradedesk.com or follow us on Facebook, Twitter, and LinkedIn.

About Chalice Custom Algorithms

Chalice empowers forward-thinking brands to own their success with transparent, tailored and intelligent algorithmic ad buying. Leveraging brand-specific KPIs, protected insights, and predictive analytics, Chalice’s lightweight tech layer is designed to help brands get ahead — and stay ahead — of their competitors. Chalice’s founders are industry veterans from New York who share a passion for the democratization of machine learning.

Ian Colley

Communications

The Trade Desk

[email protected]

KEYWORDS: United States North America California

INDUSTRY KEYWORDS: Software Internet Finance Advertising Data Management Communications Professional Services Technology

MEDIA:

Logo
Logo

It’s an Anime Explosion of Content as Funimation Is Coming to VIZIO SmartCast®

 It’s an Anime Explosion of Content as Funimation Is Coming to VIZIO SmartCast®

 SmartCast Users Will Soon Be Able to Tune into Funimation for Live and On-Demand Anime Programming Directly on their SmartCast TVs

IRVINE, Calif. & CULVER CITY, Calif.–(BUSINESS WIRE)–VIZIO (NYSE: VZIO) today announced that the Funimation app, the premiere destination streaming service for anime, will soon be available on VIZIO’s SmartCast platform. Soon millions of viewers across America can join the Funimation fan community and enjoy more than 13,000 hours of anime episodes, movies, extras, and top trending shows from Japan like My Hero Academia, Demon Slayer: Kimetsu no Yaiba, Fruits Basket, Black Clover, and Attack on Titan, all on-demand, either subtitled and/or dubbed.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210707005340/en/

Funimation is coming to VIZIO SmartCast (Photo: Business Wire)

Funimation is coming to VIZIO SmartCast (Photo: Business Wire)

The streaming service also includes fan-favorites and anime classics like Cowboy Bebop, Fullmetal Alchemist:Brotherhood and One Piece. Funimation just launched its hot summer season, with more than 20 new and returning series as well as the global smash hit,Demon Slayer -Kimetsu no Yaiba- The Movie: Mugen Train, which arrived on the service last month after being in theaters this Spring.

Now fans can enjoy a true cinematic experience thanks to VIZIO’s incredible picture quality and top-of-the-line sound experience. VIZIO TVs display the deepest blacks and highest peak brightness in their class thanks to an unbeatable 4K HDR picture in the V-Series models, with Quantum Color technology across the M-Series Quantum, P-Series Quantum, and P-Series Quantum X TVs and with the latest TV collection, Funimation is just a voice command away with the VIZIO Voice remote.

A cinematic experience is not only about picture quality, but also immersive audio. By pairing a VIZIO SmartCast TV with one of VIZIO’s award-winning sound bars, Funimation fans will not only see every detail, but can experience a fully immersive, room-shaking Dolby Atmos® and DTS:X® floor to ceiling sound.

“VIZIO is committed to delivering the best content possible for audiences of every genre,” said Katherine Pond, Vice President of Business Development for VIZIO. “We’re excited to bring Funimation movies and TV shows to life for millions of SmartCast anime fans in their own homes like never before.”

“Our partnership with VIZIO now completes Funimation’s availability on all major distribution platforms and truly lets us be where every fan is,” said Kaliel Roberts, Chief Product Officer at Funimation Global Group. “Whether or not it’s text-to-speech navigation, search capabilities or curated recommendations, the custom-built Funimation user experience for anime fans on VIZIO will be amazing.”

Funimation is available in more than 50 countries, including in the United States and Canada, starting at $5.99 per month, and a Premium Plus version available for $7.99 per month. VIZIO SmartCast users can find the Funimation streaming service in the app row on the SmartCast Home Screen.

In addition to the Funimation streaming app, VIZIO provides convenient access to on-screen apps like Apple TV+, Disney+, Hulu, Netflix, Paramount+, Peacock, Prime Video and YouTube TV. It also includes support for Apple AirPlay 2 & Chromecast built-in, allowing viewers to stream, control, and share content from their phone, tablet, or laptop directly onto the big screen. VIZIO SmartCast is continuously enhancing the platform with new features and content, so users have endless entertainment options, all while staying healthy and safe in their homes.

About Funimation

If it’s anime, it’s Funimation.

As the market leader in anime, we proudly deliver incredible fan experiences across television, feature films, events, collectibles, and the Funimation App.

Headquartered in the US and connected by a global network, our anime-obsessed team serves the fandom in over 52 countries and 10 languages. With over 400 team members, we’ve built a global community where fans and their passion will always have a place to belong.

Funimation is an independently-operated joint venture between US-based Sony Pictures Entertainment, and Japan’s Aniplex, a subsidiary of Sony Music Entertainment (Japan) Inc., both subsidiaries of Tokyo-based Sony Group Corporation.

Visit funimation.com and follow us on Facebook, Twitter and Instagram.

About VIZIO

Founded and headquartered in Orange County, California, VIZIO’s mission is to deliver immersive entertainment and compelling lifestyle enhancements that make our products the center of the connected home. VIZIO is driving the future of televisions through its integrated platform of cutting-edge Smart TVs and powerful SmartCast operating system. VIZIO also offers a portfolio of innovative sound bars that deliver consumers an elevated audio experience. VIZIO’s platform gives content providers more ways to distribute their content and advertisers more tools to target and dynamically serve ads to a growing audience that is increasingly transitioning away from linear TV.

For more information, visit VIZIO.com and follow VIZIO on Facebook, Twitter, and Instagram.

Press Contact for VIZIO:

Melissa Hourigan

Fabric Media

720-608-1919

[email protected]

Press Contact for Funimation:

Brian Eley

[email protected]

KEYWORDS: California United States North America

INDUSTRY KEYWORDS: Technology Mobile/Wireless Entertainment Mobile Entertainment Audio/Video Other Entertainment TV and Radio Film & Motion Pictures Consumer Electronics

MEDIA:

Logo
Logo
Photo
Photo
Funimation is coming to VIZIO SmartCast (Photo: Business Wire)

Hudson Pacific Properties Announces Dates for Second Quarter Earnings Release and Conference Call

Hudson Pacific Properties Announces Dates for Second Quarter Earnings Release and Conference Call

LOS ANGELES–(BUSINESS WIRE)–Hudson Pacific Properties, Inc. (NYSE: HPP) today announced it will release second quarter financial results after the market closes on Tuesday, August 3, 2021. The company will hold a conference call to discuss the results at 11:00 a.m. PT / 2:00 p.m. ET on Wednesday, August 4, 2021.

Please dial (877) 407-0784 to access the call. International callers should dial (201) 689-8560. A live, listen-only webcast can be accessed via the Investors section of the company’s website at HudsonPacificProperties.com, where a replay of the call will be available.

A replay will also be available beginning August 4, 2021 at 2:00 p.m. PT / 5:00 p.m. ET, through August 18, 2021 at 8:59 p.m. PT / 11:59 p.m. ET, by dialing (844) 512-2921 and entering the passcode 13720804. International callers should dial (412) 317-6671 and enter the same passcode.

About Hudson Pacific Properties

Hudson Pacific is a real estate investment trust with a portfolio of office and studio properties totaling nearly 20 million square feet, including land for development. Focused on premier West Coast epicenters of innovation, media and technology, its anchor tenants include Fortune 500 and leading growth companies such as Google, Netflix, Riot Games, Square, Uber and more. Hudson Pacific is publicly traded on the NYSE under the symbol HPP and listed as a component of the S&P MidCap 400 Index. For more information visit HudsonPacificProperties.com.

Forward-Looking Statements Regarding Hudson Pacific Properties

This press release may contain forward-looking statements within the meaning of the federal securities laws. Forward-looking statements relate to expectations, beliefs, projections, future plans and strategies, anticipated events or trends and similar expressions concerning matters that are not historical facts. In some cases, you can identify forward-looking statements by the use of forward-looking terminology such as “may,” “will,” “should,” “expects,” “intends,” “plans,” “anticipates,” “believes,” “estimates,” “predicts,” or “potential” or the negative of these words and phrases or similar words or phrases that are predictions of or indicate future events or trends and that do not relate solely to historical matters. Forward-looking statements involve known and unknown risks, uncertainties, assumptions and contingencies, many of which are beyond Hudson Pacific’s control, which may cause actual results to differ significantly from those expressed in any forward-looking statement. All forward-looking statements reflect Hudson Pacific’s good faith beliefs, assumptions and expectations, but they are not guarantees of future performance. Furthermore, Hudson Pacific disclaims any obligation to publicly update or revise any forward-looking statement to reflect changes in underlying assumptions or factors, of new information, data or methods, future events or other changes. For a further discussion of these and other factors that could cause Hudson Pacific’s future results to differ materially from any forward-looking statements, see the section entitled “Risk Factors” in Hudson Pacific’s Annual Report on Form 10-K filed with the Securities and Exchange Commission, or SEC, and other risks described in documents subsequently filed by Hudson Pacific from time to time with the SEC.

Investor Contact:

Laura Campbell

Executive Vice President, Investor Relations & Marketing

(310) 622-1702

[email protected]

Media Contact:

Laura Murray

Director, Communications

(310) 622-1781

[email protected]

KEYWORDS: United States North America California

INDUSTRY KEYWORDS: Professional Services Residential Building & Real Estate Commercial Building & Real Estate Finance Construction & Property REIT

MEDIA:

Logo
Logo

County of Fresno Switches to Rimini Street Support and Reinvests Annual Oracle Support Cost Savings in Growing Its Public Programs

County of Fresno Switches to Rimini Street Support and Reinvests Annual Oracle Support Cost Savings in Growing Its Public Programs

Largest agricultural producing County in the U.S. saves $800,000 in Oracle Database and PeopleSoft application support; Enables County to pass on cost savings to departments that provide direct services to the community

LAS VEGAS–(BUSINESS WIRE)–Rimini Street, Inc. (Nasdaq: RMNI), a global provider of enterprise software products and services, the leading third-party support provider for Oracle and SAP software products and a Salesforce partner, today announced the County of Fresno in California has switched to Rimini Street Support for its Oracle Database and Fusion Middleware software and PeopleSoft applications. The County’s Internal Services Department (ISD) had long considered replacing the support and maintenance for its Oracle suite of products as part of its continued focus to keep costs down and streamline IT operations. By switching to Rimini Street Support, the County of Fresno was able to liberate $800,000 of the County’s annual Oracle support costs. This enabled the department to reduce service rates charged to internal County stakeholders and increase funding for community-focused projects and critical support initiatives for its residents. In addition, the County of Fresno can now maximize the investment in its Oracle system for a minimum of 15 years from the time they switched to Rimini Street without requiring costly, labor-intensive and low-value upgrades.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210707005268/en/

County of Fresno Switches to Rimini Street Support and Reinvests Annual Oracle Support Cost Savings in Growing Its Public Programs (Photo: Business Wire)

County of Fresno Switches to Rimini Street Support and Reinvests Annual Oracle Support Cost Savings in Growing Its Public Programs (Photo: Business Wire)

Improved Enterprise Software Support Touches All Aspects of County Operations

Located in central California, the County of Fresno is home to nearly one million residents in 15 cities, including Fresno. With 1.88 million acres of farmland and over 300 different crops, Fresno County is the number one agricultural producing county in the U.S. and ships goods to 95 countries worldwide. The ISD supports the county’s myriad public-facing divisions and is constantly searching for cost optimizations it can pass along to the departments directly serving the community. The ISD’s Information Technology Division provides the core infrastructure support for all the county’s networking, programming, service desk and enterprise resource planning (ERP) needs. In addition, numerous divisions within the local government utilize Oracle Database and Fusion Middleware software and PeopleSoft applications for financial and HR functions to manage the billions of dollars of budget run through the system, which supports the county’s 8,000 employees. For years the County had tried to collaborate with Oracle to reduce its support costs, but these efforts proved unsuccessful. As a result, the County switched to Rimini Street Support and now receives faster response times and proactive guidance from the Company’s expert engineers. This, in turn, has freed up the County’s internal IT personnel to focus on more critical business initiatives.

“Partnering with Rimini Street has enabled us to continue advancing a cultural shift towards exploring new ways of doing business. Every dollar county departments save on ISD’s services is money that can be spent on programs for the community,” said Robert Bash, director of internal services and chief information officer, County of Fresno. “The savings have given us the financial flexibility to begin exploring what is next for our infrastructure. We’re able to invest in developing a roadmap for the county, all while remaining cost-neutral for our users.”

Personalized Support from Expert Engineers 24/7/365

The County of Fresno, along with all Rimini Street clients, is assigned a Primary Support Engineer, backed by a team of functional and technical experts, who have an average of more than 15 years’ experience in the client’s software system. The Company also benefits from Rimini Street’s ultra-responsive service level agreement of 10-minute response times for critical Priority 1 cases. Rimini Street also handles all of the County’s tax, legal and regulatory updates, ensuring security and compliance requirements are met according to state guidelines.

“Rimini Street recently helped create a legislation update for us, which, according to our PeopleSoft team, took substantially less time to implement than previous updates from Oracle. Rimini Street tailored a patch specifically to our environment, so our team didn’t need to waste time applying code that we don’t need, like global payroll,” said Sheri Walden, deputy director of information technology, County of Fresno. “Rimini Street is focused on the support and success of our organization, not just delivering a product. The Rimini Street team initiates meaningful conversation and is constantly probing for how we can improve our infrastructure or better focus on the unique needs of our stakeholders.”

“By switching to Rimini Street, the County of Fresno was able to reduce IT costs, maintain legislative security and compliance, and maximize efficiencies within its IT team to focus its resources on strategic and community initiatives,” said Gerard Brossard, chief operating officer, Rimini Street. “Rimini Street currently supports public sector and government agencies and departments around the world, helping them to significantly reduce their vendor support and maintenance costs, better manage their IT resources – people, time and money – and invest in transformative projects that better meet the needs of their communities.”

Learn more about County of Fresno’s success with Rimini Street.

About Rimini Street, Inc.

Rimini Street, Inc. (Nasdaq: RMNI), a Russell 2000® Company, is a global provider of enterprise software products and services, the leading third-party support provider for Oracle and SAP software products and a Salesforce partner. The Company offers premium, ultra-responsive and integrated application management and support services that enable enterprise software licensees to save significant costs, free up resources for innovation and achieve better business outcomes. To date, more than 4,000 Fortune 500, Fortune Global 100, midmarket, public sector and other organizations from a broad range of industries have relied on Rimini Street as their trusted application enterprise software products and services provider. To learn more, please visit http://www.riministreet.com, follow @riministreet on Twitter and find Rimini Street on Facebook and LinkedIn.

Forward-Looking Statements

Certain statements included in this communication are not historical facts but are forward-looking statements for purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995. Forward-looking statements generally are accompanied by words such as “may,” “should,” “would,” “plan,” “intend,” “anticipate,” “believe,” “estimate,” “predict,” “potential,” “seem,” “seek,” “continue,” “future,” “will,” “expect,” “outlook” or other similar words, phrases or expressions. These forward-looking statements include, but are not limited to, statements regarding our expectations of future events, future opportunities, global expansion and other growth initiatives and our investments in such initiatives. These statements are based on various assumptions and on the current expectations of management and are not predictions of actual performance, nor are these statements of historical facts. These statements are subject to a number of risks and uncertainties regarding Rimini Street’s business, and actual results may differ materially. These risks and uncertainties include, but are not limited to, the duration of and operational and financial impacts on our business of the COVID-19 pandemic and related economic impact, as well as the actions taken by governmental authorities, clients or others in response to the COVID-19 pandemic; catastrophic events that disrupt our business or that of our current and prospective clients, changes in the business environment in which Rimini Street operates, including inflation and interest rates, and general financial, economic, regulatory and political conditions affecting the industry in which Rimini Street operates; adverse developments in pending litigation or in the government inquiry or any new litigation; our need and ability to raise additional equity or debt financing on favorable terms and our ability to generate cash flows from operations to help fund increased investment in our growth initiatives; the sufficiency of our cash and cash equivalents to meet our liquidity requirements; the terms and impact of our outstanding 13.00% Series A Preferred Stock; our ability to maintain an effective system of internal control over financial reporting, and our ability to remediate identified material weaknesses in our internal controls, including in relation to the accounting treatment of our warrants; changes in taxes, laws and regulations; competitive product and pricing activity; difficulties of managing growth profitably; the customer adoption of our recently introduced products and services, including our Application Management Services (AMS), Rimini Street Advanced Database Security, and services for Salesforce Sales Cloud and Service Cloud products, in addition to other products and services we expect to introduce in the near future; the loss of one or more members of Rimini Street’s management team; uncertainty as to the long-term value of Rimini Street’s equity securities; and those discussed under the heading “Risk Factors” in Rimini Street’s Quarterly Report on Form 10-Q filed on May 10, 2021, and as updated from time to time by Rimini Street’s future Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q, Current Reports on Form 8-K, and other filings by Rimini Street with the Securities and Exchange Commission. In addition, forward-looking statements provide Rimini Street’s expectations, plans or forecasts of future events and views as of the date of this communication. Rimini Street anticipates that subsequent events and developments will cause Rimini Street’s assessments to change. However, while Rimini Street may elect to update these forward-looking statements at some point in the future, Rimini Street specifically disclaims any obligation to do so, except as required by law. These forward-looking statements should not be relied upon as representing Rimini Street’s assessments as of any date subsequent to the date of this communication.

© 2021 Rimini Street, Inc. All rights reserved. “Rimini Street” is a registered trademark of Rimini Street, Inc. in the United States and other countries, and Rimini Street, the Rimini Street logo, and combinations thereof, and other marks marked by TM are trademarks of Rimini Street, Inc. All other trademarks remain the property of their respective owners, and unless otherwise specified, Rimini Street claims no affiliation, endorsement, or association with any such trademark holder or other companies referenced herein.

Michelle McGlocklin

Rimini Street, Inc.

+1 925 523-8414

[email protected]

KEYWORDS: United States North America California Nevada

INDUSTRY KEYWORDS: Data Management Security Technology Software Networks Internet

MEDIA:

Logo
Logo
Photo
Photo
County of Fresno Switches to Rimini Street Support and Reinvests Annual Oracle Support Cost Savings in Growing Its Public Programs (Photo: Business Wire)

The ODP Corporation Releases 2021 Sustainability Report

The ODP Corporation Releases 2021 Sustainability Report

Report Presents the Company’s Environmental, Social and Governance (ESG) Practices and Goals

BOCA RATON, Fla.–(BUSINESS WIRE)–
The ODP Corporation (NASDAQ:ODP), a leading provider of business services, products and digital workplace technology solutions through an integrated B2B distribution platform with an online presence and approximately 1,100 stores, today announced the release of the company’s 2021 Corporate Sustainability Report, which provides information on environmental, social and governance (ESG) practices and goals for Office Depot, CompuCom and Grand & Toy.

“The ODP Corporation’s sustainability platform includes a variety of programs and initiatives in place to support our commitment to be a responsible corporation and help our suppliers and customers do the same,” said Gerry Smith, chief executive officer for The ODP Corporation. “I’m proud to close out our 2018 public-facing sustainability goals by exceeding our targets. We will set new baselines with meaningful goals in regard to our continued commitment to decreasing the company’s environmental impact.”

The ODP Corporation’s 2021 Corporate Sustainability Report highlights resiliency during the COVID-19 pandemic, with a focus on associate well-being, as well as maintaining business operations. The report also showcases the progress made on the company’s public-facing sustainability goals around energy consumption, transportation emissions and cube utilization:

  • The company had already exceeded its goal in 2019 to reduce energy consumption by 2021, with a 44% decrease in facility energy consumption since 2016.
  • Miles per gallon in Office Depot’s private fleet increased 18% since 2018, exceeding the goal of 15%.
  • Office Depot improved cube utilization by 14% since 2018, exceeding the goal of 10%.

Other accomplishments highlighted in the 2021 report include:

Planet:

  • 11% reduction in GHG (greenhouse gas) emissions since 2019
  • 15,365 MT waste diverted from the landfill
  • Recycled more than 6 million pounds of e-waste from customers
  • The Office Depot Chemicals Management Policy was expanded and a Beyond Restricted Substances List (BRSL) was published for the first time in 2020.

People:

  • Associate Resource Groups expanded to 14, with four new ARGs established between Office Depot, CompuCom and Grand & Toy, including groups for Asian Professionals, Men of Color, and Women in Leadership.
  • Over $10 Million worth of in-kind products were donated to community organizations and $2 Million was donated directly to COVID-19 relief programs.
  • 18,000 fully stocked backpacks, gift cards and supplies were given to students and teachers at 25 schools across the country through the Office Depot Start Proud!® program.

Prosperity:

  • By partnering with minority-, women-, veteran-, disabled-, LGBTQ+ -owned and small businesses through Office Depot’s diverse supplier program, diverse businesses reached $270+ million in spend and sales.
  • 31% of total Office Depot sales were greener products.
  • The ODP Corporation created Elevate Together™ powered by Round It Up America® – a nonprofit initiative designed to address systemic discrimination by accelerating the creation, growth and prosperity of Black- and Hispanic-owned small businesses.

For more information about sustainability at The ODP Corporation, please view the full 2021 Corporate Sustainability Report.

About The ODP Corporation

The ODP Corporation (NASDAQ:ODP) is a leading provider of business services and supplies, products and digital workplace technology solutions to small, medium and enterprise businesses, through an integrated business-to-business (B2B) distribution platform, which includes world-class supply chain and distribution operations, dedicated sales professionals and technicians, online presence, and approximately 1,100 stores. Through its banner brands Office Depot®, OfficeMax®, CompuCom® and Grand&Toy®, as well as others, the company offers its customers the tools and resources they need to focus on their passion of starting, growing and running their business. For more information, visit news.theodpcorp.com and investor.theodpcorp.com.

The ODP Corporation and Office Depot are trademarks of The Office Club, Inc. OfficeMax is a trademark of OMX, Inc. CompuCom is a trademark of CompuCom Systems, Inc. Grand&Toy is a trademark of Grand & Toy, LLC in Canada. ©2021 Office Depot, LLC. All rights reserved. Any other product or company names mentioned herein are the trademarks of their respective owners.

Rebecca Rakitin

561-438-1450

[email protected]

Danny Jovic

561-438-1594

[email protected]

KEYWORDS: United States North America Florida

INDUSTRY KEYWORDS: Online Retail Other Retail Professional Services Philanthropy Office Products Specialty Consumer Environment Retail Other Consumer Other Professional Services Other Philanthropy

MEDIA:

Logo
Logo

AXIS Re Appoints AXIS Insurance’s Lopiccolo to Drive Global Broker Engagement

AXIS Re Appoints AXIS Insurance’s Lopiccolo to Drive Global Broker Engagement

PEMBROKE, Bermuda–(BUSINESS WIRE)–
AXIS Re, the reinsurance business segment of AXIS Capital Holdings Limited (“AXIS Capital”) (NYSE:AXS), today announced the appointment of Matt LoPiccolo as Strategic Account Executive, Global Brokers for its client engagement initiative, AXIS Re Strategic Partners. Mr. LoPiccolo joins the Reinsurance team after having served as Head of US Digital Distribution within the Company’s Insurance segment. He will continue to be based in New York and will report to Jason Busti, AXIS Re President of North America and Head of AXIS Re Strategic Partners.

In this newly-created role, Mr. LoPiccolo will be responsible for enhancing relationships with AXIS Re’s Global Brokers across all lines of business, and building out others. He will also be responsible for working collectively with AXIS Re’s Global Brokers to develop new business opportunities and collaborate on solutions. AXIS Re Strategic Partners, launched in 2018, is a dedicated team to serve select clients and brokers.

“Matt has a strong track record of building and growing broker and client relationships, as well as the perspective of having worked on the broker side of the business,” said Mr. Busti. “His promotion also speaks to the Company’s One AXIS philosophy and the priority that we place on creating career mobility and growth opportunities for our talent. Matt will be a fantastic addition to AXIS Re.”

Mr. LoPiccolo has more than 24 years of industry experience across the broking and insurance sectors. He joined AXIS Insurance in 2016, holding roles such as Head of US Distribution for the Professional Lines Division and Head of US Digital Distribution. Prior to AXIS, Mr LoPiccolo held various roles at AIG within its sales and marketing and distribution divisions. He began his career at Marsh & McLennan.

Mr. LoPiccolo’s appointment is effective July 6.

About AXIS Capital

AXIS Capital, through its operating subsidiaries, is a global provider of specialty lines insurance and treaty reinsurance with shareholders’ equity of $5.2 billion at March 31, 2021 and locations in Bermuda, the United States, Europe, Singapore and Canada. Its operating subsidiaries have been assigned a rating of “A+” (“Strong”) by Standard & Poor’s and “A” (“Excellent”) by A.M. Best. For more information about AXIS Capital, visit our website at www.axiscapital.com.

Follow AXIS Capital on LinkedIn and Twitter.

Investor Contact

Matt Rohrmann

AXIS Capital Holdings Limited

[email protected]

(212) 940-3339

Media Contact

Anna Kukowski

AXIS Capital Holdings Limited

[email protected]

(212) 715-3574

KEYWORDS: Bermuda Caribbean

INDUSTRY KEYWORDS: Professional Services Insurance Finance

MEDIA:

Logo
Logo

Virpax Pharmaceuticals Provides Progress Update on Product Candidates

Virpax Pharmaceuticals Provides Progress Update on Product Candidates

BERWYN, Pa.–(BUSINESS WIRE)–
Virpax® Pharmaceuticals Inc. (“Virpax” or the “Company”) (NASDAQ:VRPX), today is providing a progress update on its pipeline of product candidates following the Company’s initial public offering (the “IPO”) in mid-February of 2021.

Chairman and CEO Anthony P. Mack commented, “Our goal following our IPO was to become a clinical stage company as quickly as possible while preserving our cash and utilizing grants to fund product development efforts where appropriate. To date, I believe we have made solid progress towards these goals. We are making refinements to some formulations which we believe will improve manufacturability, and possibly extend patent life. We are also evaluating additional indications for our unique delivery technologies. Finally, we plan to begin initial Investigational New Drug Application (“IND”) enabling studies shortly on several of our existing programs and recently submitted a pre-IND briefing document to the U.S. Food and Drug Administration (“FDA”) for MMS019, our intranasal molecular masking spray.”

Epoladerm™

Epoladerm is Virpax’s metered-dose diclofenac spray film product candidate that is currently being evaluated for two indications, acute musculoskeletal pain and chronic osteoarthritis of the knee pain (OSF200). The Company will begin a series of IND enabling toxicity studies which are expected to take from eight months to one year to complete. Upon successful completion of these studies, the Company intends to submit an IND application to the FDA, including a trial design for a Phase I study.

For the chronic osteoarthritis pain of the knee indication, Virpax is planning to conduct a Phase I study to evaluate the relative bioavailability, pharmacokinetics, and safety of its product candidate, OSF200, compared with Pennsaid topical solution. No date for trial initiation or timeline has been determined for OSF200 at this time.

Probudur™

Probudur is Virpax’s injectable bupivacaine liposomal hydrogel for postoperative pain management, which we believe to have improved onset and extended duration of action compared to existing treatment options. Charles River Laboratories has been engaged to perform seven preclinical animal studies during the second half of 2021, including method, dosage, and toxicity as part of the required FDA enabling trials for an IND for Probudur. However, the Company has elected to strategically delay these trials in order to enhance the formulation of Probudur to increase stability for manufacturing purposes and to possibly extend the lifetime of a relevant patent.

Envelta™

Envelta is Virpax’s endogenous enkephalin intranasal spray for acute and chronic pain, including pain associated with cancer. The IND enabling studies for Envelta are being performed under a Cooperative Research and Development Agreement (“CRADA”) entered into by Virpax and the National Center for Advancing Translational Sciences (“NCATS”). The Company recently announced that it intends to use these studies as a source for INDs for two additional potential indications, cancer pain and Post-Traumatic Stress Disorder. To date, 2 of the 4 planned initial in vitro studies have been successfully completed. These pre-clinical studies under the CRADA will be conducted through 2021 and early 2022.

MMS019

MMS019 is Virpax’s high-density intranasal molecular masking spray being developed as an anti-viral barrier that will be used as an adjuvant to barrier-based personal protective equipment. The Company recently announced that results from an animal study of MMS019 demonstrated inhibited viral replication and decreased levels of virus in animal brain tissue. Virpax engaged Syneos Health to assist with the regulatory pathway and drug development trials required to file an NDA for FDA approval. The Company has submitted a pre-IND briefing package to the FDA.

“We remain excited about the opportunities that we have ahead of us. We will be providing additional newsworthy information through our filings with the SEC or through news releases,” concluded Mr. Mack.

About Virpax Pharmaceuticals

Virpax is developing branded, non-addictive pain management product candidates using its proprietary technologies that optimize target drug delivery. Virpax is initially seeking FDA approval using its three patented drug delivery platforms. Epoladerm™ is a topical diclofenac metered-dose spray film formulation being developed to manage acute musculoskeletal pain and osteoarthritis. Probudur™ is a single injection liposomal bupivacaine formulation being developed to manage post-operative pain. Envelta™ is an intranasal molecular envelope enkephalin formulation being developed to manage acute and chronic pain, including pain associated with cancer. Virpax is also using its intranasal Molecular Envelope Technology (MET) to develop its PES200 product candidate to manage post-traumatic stress disorder (PTSD) and its MMS019 product candidate to inhibit viral replication caused by influenza or SARS-CoV-2. For more information, please visit www.virpaxpharma.com.

Forward-Looking Statement

This press release contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and Private Securities Litigation Reform Act, as amended, including those relating to the Company’s planned clinical trials, product development, clinical and regulatory timelines, market opportunity, competitive position, possible or assumed future results of operations, business strategies, potential growth opportunities and other statements that are predictive in nature. These forward-looking statements are based on current expectations, estimates, forecasts and projections about the industry and markets in which we operate and management’s current beliefs and assumptions.

These statements may be identified by the use of forward-looking expressions, including, but not limited to, “expect,” “anticipate,” “intend,” “plan,” “believe,” “estimate,” “potential,” “predict,” “project,” “should,” “would” and similar expressions and the negatives of those terms. These statements relate to future events or our financial performance and involve known and unknown risks, uncertainties, and other factors, including the potential impact of the recent COVID-19 pandemic and the potential impact of sustained social distancing efforts, on the Company’s operations, clinical development plans and timelines, which may cause actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Such factors include those set forth in the Company’s filings with the Securities and Exchange Commission. Prospective investors are cautioned not to place undue reliance on such forward-looking statements, which speak only as of the date of this press release. The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise.

Christopher M. Chipman, CPA

Chief Financial Officer

[email protected]

610-727-4597

Or

Betsy Brod

Affinity Growth Advisors

[email protected]

212-661-2231

KEYWORDS: United States North America Pennsylvania

INDUSTRY KEYWORDS: Research Mental Health FDA Clinical Trials Biotechnology Managed Care Pharmaceutical Health Science Oncology

MEDIA:

Logo
Logo

Emerson Simplifies Data Management for Manufacturers with New Enterprise-Level Software Solution

Emerson Simplifies Data Management for Manufacturers with New Enterprise-Level Software Solution

Plantweb Optics Data Lake helps companies unify data at scale to improve profitability

AUSTIN, Texas–(BUSINESS WIRE)–
Global industrial software and technology leader Emerson (NYSE: EMR) today announced the launch of its Plantweb™ Optics Data Lake, an enterprise-level data management software solution that helps manufacturers reduce data complexity so that they can fully leverage operations data across a production site or from multiple sites to improve profitability enterprise-wide.

This new advanced data management solution securely identifies, collects and contextualizes disparate data, at scale, either on-premises or using cloud technology. Today, this valuable manufacturing data is often in different formats and siloed across a plant, posing significant impediments to a company’s digital transformation initiatives. By effectively unifying this data, companies can establish a sound data foundation that can be leveraged by various digital solutions.

For example, Emerson’s data lake software, which is integrated into the Plantweb Optics platform, can seamlessly work with advanced analytics applications powered by machine learning and artificial intelligence – or connect with other providers’ analytics and dashboard toolkits – to drive performance improvement and increase revenue. Because this software was designed to serve as a centralized information technology (IT) solution that draws from Emerson’s broad operational technology (OT) expertise, it reduces the need for data science specialists.

“A solid data management foundation is critical to every digital transformation program,” said Stuart Harris, group president for digital transformation at Emerson. “Most manufacturers say they have lots of data but aren’t able to turn it into valuable business insights. Our Plantweb Optics Data Lake software enables users to collect, manage and contextualize vast amounts of OT data from diverse sources, giving users the power to maximize operational performance by implementing advanced applications on an enterprise-wide scale.”

Emerson’s Plantweb Optics Data Lake runs on various cloud-computing platforms, enabling companies to implement a wide range of use cases from analytics applications that make use of machine learning to KPIs and dashboards, digital twins and other applications for improving reliability and sustainability. Effectively bridging the gap between OT and IT domains, this software seamlessly consolidates manufacturing data from a variety of systems, protocols and data architectures – even legacy systems – across a plant and multiple facilities by moving it into the cloud and ensuring that it’s ready for use.

“Many legacy systems at manufacturing sites across the world are already over a decade old, and they’re often isolated from each other, impeding teams from effectively accessing data at scale for operational improvements,” said Peter Zornio, chief technology officer of Emerson’s Automation Solutions business. “Aggregating information between systems without disrupting production is extremely complex and difficult. Emerson’s software allows users to securely manage operational data centrally, scale it easily and gain critical insight into their operations at the enterprise level.”

With applicability in process, hybrid and discrete manufacturing industries including life sciences, chemical, metals and mining, power and water, and energy industries, Plantweb Optics Data Lake is part of Emerson’s award-winning Plantweb digital ecosystem of technologies, software and services.

About Emerson

Emerson (NYSE: EMR), headquartered in St. Louis, Missouri (USA), is a global technology and engineering company providing innovative solutions for customers in industrial, commercial and residential markets. Our Automation Solutions business helps process, hybrid and discrete manufacturers maximize production, protect personnel and the environment while optimizing their energy and operating costs. Our Commercial and Residential Solutions business helps ensure human comfort and health, protect food quality and safety, advance energy efficiency and create sustainable infrastructure. For more information visit Emerson.com.

For Emerson

Denise Clarke

[email protected]

512.587.5879

KEYWORDS: United States North America Texas Missouri

INDUSTRY KEYWORDS: Electronic Design Automation Engineering Data Management Technology Manufacturing Software

MEDIA:

Logo
Logo

Regions Financial Provides Quarterly Earnings Release Dates for 2022

Regions Financial Provides Quarterly Earnings Release Dates for 2022

Executives will host conference calls reviewing each quarter’s results.

BIRMINGHAM, Ala.–(BUSINESS WIRE)–Regions Financial Corp. (NYSE:RF) on Wednesday announced the dates on which the company plans to issue its quarterly earnings results in 2022. Regions will announce results pre-market open on each of the following dates, and executives will host conference calls each quarter to review the results.

  • Fourth Quarter 2021 Results: To be announced pre-market open on Friday, Jan. 21, 2022. Regions executives will host the conference call at 10 a.m. ET on that date. The call will be accessible through Regions’ Investor Relations website, https://ir.regions.com/.
  • First Quarter 2022 Results: To be announced pre-market open on Friday, April 22, 2022. Regions executives will host the conference call at 10 a.m. ET on that date. The call will be accessible through Regions’ Investor Relations website, https://ir.regions.com/.
  • Second Quarter 2022 Results: To be announced pre-market open on Friday, July 22, 2022. Regions executives will host the conference call at 10 a.m. ET on that date. The call will be accessible through Regions’ Investor Relations website, https://ir.regions.com/.
  • Third Quarter 2022 Results: To be announced pre-market open on Friday, Oct. 21, 2022. Regions executives will host the conference call at 10 a.m. ET on that date. The call will be accessible through Regions’ Investor Relations website, https://ir.regions.com/.

Regions will issue a detailed announcement confirming the date and time of the earnings release and conference call for each quarter. A link to the live audio webcast of the conference call, along with supplementary materials, will be made available on Regions’ Investor Relations website, and dial-in information for audio replays of the conference calls will be provided at a later date.

About Regions Financial Corporation

Regions Financial Corporation (NYSE:RF), with $153 billion in assets, is a member of the S&P 500 Index and is one of the nation’s largest full-service providers of consumer and commercial banking, wealth management, and mortgage products and services. Regions serves customers across the South, Midwest and Texas, and through its subsidiary, Regions Bank, operates more than 1,300 banking offices and approximately 2,000 ATMs. Regions Bank is an Equal Housing Lender and Member FDIC. Additional information about Regions and its full line of products and services can be found at www.regions.com.

Media Contact:

Jeremy D. King

205-264-4551

Investor Relations Contact:

Dana Nolan

205-264-7040

Regions News Online: regions.doingmoretoday.com

Regions News on Twitter: @RegionsNews

KEYWORDS: Alabama United States North America

INDUSTRY KEYWORDS: Banking Professional Services Finance

MEDIA:

Logo
Logo